Immuron Begins Recruitment Of Travelan Clinical Study
Portfolio Pulse from Benzinga Newsdesk
Immuron has received approval from the U.S. Army Medical Research and Development Command to proceed with its planned clinical trial in the United States and has begun recruitment for the Travelan study.
May 30, 2023 | 10:06 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Immuron receives approval to proceed with its Travelan clinical trial in the United States, which may positively impact the company's stock price.
Immuron's approval from the U.S. Army Medical Research and Development Command to proceed with its clinical trial in the United States is a significant milestone for the company. This news may lead to increased investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100